ClinicalTrials.gov
public full text
Public Domain
Sodium Stibogluconate in the MDS/AML With One of the 65 Defined p53 Mutations
To evaluate the safety and effectiveness of Sodium Stibogluconate in the treatment of myelodysplastic syndrome/acute myeloid leukemia (MDS/AML) with p53 mutation from a defined list. The list includes 65 p53 mutations that were experimentally confirmed to be pharmacologically restored with tumor-suppressive function by antimonials.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Study of NMS-03597812 in Adult Patients With Relapsed/Refractory Acute Myeloid Leukemia#1140742
- Decitabine and Arsenic Trioxide for Myelodysplastic Syndrome(MDS)#1088824
- Sorafenib and 5-Azacitidine in Acute Leukemia + Myelodysplastic Syndrome#1151729
- Single Agent Decitabine in TP53 Mutated Relapsed/Refractory Acute Myeloid Leukemia#863606
- Repurposed Drugs to Improve Haematological Responses in Myelodysplastic Syndromes#891883
Record · ID 877747
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive